<table class="infobox infobox-therapeutic"> <tr> <th class="infobox-header" colspan="2">AADC Gene Therapy for Parkinson's Disease</th> </tr> <tr> <td class="label">Measure</td> <td>Improvement</td> </tr> <tr> <td class="label">OFF-medication UPDRS Part III</td> <td>30-50% improvement</td> </tr> <tr> <td class="label">ON-time without dyskinesia</td> <td>Increased by 2-4 hours/day</td> </tr> <tr> <td class="label">OFF-time</td> <td>Reduced by 2-4 hours/day</td> </tr> <tr> <td class="label">Levodopa dose equivalent</td> <td>Reduced by 30-50%</td> </tr> </table>
Introduction
Overview
Aromatic L-amino acid decarboxylase (AADC) gene therapy is an innovative treatment approach for Parkinson's disease that aims to restore dopamine synthesis in the brain. By delivering the DDC gene (encoding AADC) directly to the striatum, this therapy enables [neurons](/entities/neurons) to convert levodopa to dopamine, potentially providing more consistent motor symptom relief[@aadc]. [@aadc]
AADC gene therapy represents one of the first successful gene therapy approaches for a neurodegenerative disease and has received regulatory approval in some regions[@aavaadc]. [@aavaadc]
Background
The Dopamine Synthesis Pathway
In the normal brain, dopamine is synthesized through a two-step process: [@longterm]
Tyrosine hydroxylase (TH) converts tyrosine to L-DOPA
AADC converts L-DOPA to dopamine
...
AADC Gene Therapy for Parkinson's Disease
<table class="infobox infobox-therapeutic"> <tr> <th class="infobox-header" colspan="2">AADC Gene Therapy for Parkinson's Disease</th> </tr> <tr> <td class="label">Measure</td> <td>Improvement</td> </tr> <tr> <td class="label">OFF-medication UPDRS Part III</td> <td>30-50% improvement</td> </tr> <tr> <td class="label">ON-time without dyskinesia</td> <td>Increased by 2-4 hours/day</td> </tr> <tr> <td class="label">OFF-time</td> <td>Reduced by 2-4 hours/day</td> </tr> <tr> <td class="label">Levodopa dose equivalent</td> <td>Reduced by 30-50%</td> </tr> </table>
Introduction
Overview
Aromatic L-amino acid decarboxylase (AADC) gene therapy is an innovative treatment approach for Parkinson's disease that aims to restore dopamine synthesis in the brain. By delivering the DDC gene (encoding AADC) directly to the striatum, this therapy enables [neurons](/entities/neurons) to convert levodopa to dopamine, potentially providing more consistent motor symptom relief[@aadc]. [@aadc]
AADC gene therapy represents one of the first successful gene therapy approaches for a neurodegenerative disease and has received regulatory approval in some regions[@aavaadc]. [@aavaadc]
Background
The Dopamine Synthesis Pathway
In the normal brain, dopamine is synthesized through a two-step process: [@longterm]
Tyrosine hydroxylase (TH) converts tyrosine to L-DOPA
AADC converts L-DOPA to dopamine
In Parkinson's disease, the dopaminergic neurons in the substantia nigra are lost, leading to: [@voyager]
Reduced dopamine production
Reduced AADC enzyme in remaining neurons
Decreased response to levodopa over time
Rationale for AADC Gene Therapy
AADC activity declines as PD progresses
Even with high-dose levodopa, conversion to dopamine is inefficient
Restoring AADC could enhance the efficacy of levodopa
Provides continuous dopamine synthesis rather than pulsatile delivery
Therapeutic Approaches
1. AAV2-AADC (Prasinema/Sonified)
Mechanism: Adeno-associated virus serotype 2 carrying the human DDC gene [@gene]
Delivery: Bilateral infusion into the striatum (putamen)
Clinical Results:
Increased AADC activity visualized on PET scanning
Improved on time without dyskinesia
Reduced levodopa equivalent dose requirements
Benefits maintained for several years post-treatment
Regulatory Status:
Received conditional approval in Japan (2024)
Under review in US and Europe
2. VY-AADC01/VY-AADC02 (Voyager Therapeutics)
Mechanism: Optimized AAV2 vector with improved promoter for enhanced AADC expression
Delivery: Intra-putaminal infusion
Phase 1b Results:
Dose-dependent increases in AADC activity
Significant improvements in motor scores
Reduced levodopa-induced dyskinesias
Ongoing Phase 2 studies
3. AXO-Lenti-PD (Axovant)
Mechanism: Lentiviral vector delivering AADC, along with TH and GCH1
Rationale: Multi-gene approach to restore complete dopamine biosynthesis pathway
Status: Clinical trials ongoing
Patient Selection
Ideal Candidates
Patients with advanced Parkinson's disease
Good response to levodopa but experiencing motor fluctuations
Stable on levodopa/carbidopa regimen
No significant cognitive impairment
No contraindications for neurosurgery
Exclusion Criteria
Significant psychiatric disease
Dementia or severe cognitive impairment
Atypical Parkinsonism
Previous gene therapy procedures
Immunosuppression
Clinical Outcomes
Motor Improvements
Durability
Benefits observed for up to 5+ years in long-term follow-up
Gradual decline in PET signal over time but maintained clinical benefit
May require repeat treatment in the future
Safety Profile
Generally well-tolerated
Most common adverse events related to surgical procedure
Intracranial hemorrhage risk (~2-5%)
No significant immune reactions against the vector
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) 🔄
[Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄